Oct 2026· Journal of Neurological Sciences· Vol 491, pp.
126204
· 0 citations· 43 references
Medicine
TL;DR
Omav confirmed a favorable safety and tolerability profile in adult patients with FRDA in a real-world setting after 48 weeks of treatment, and a sustained reduction in IL-6 levels supports a potential direct immunomodulatory effect of the drug, consistent with its proposed disease-modifying activity.
Abstract
Background
Friedreich's Ataxia (FRDA) is the most common inherited spinocerebellar ataxia and is caused by a homozygous GAA trinucleotide repeat expansion in the frataxin (FXN) gene, leading to reduced intramitochondrial frataxin expression with a consequent progressive neurodegeneration and multisystem involvement. Neuroinflammatory pathways may contribute to FRDA pathophysiology and IL-6 represents a biologically relevant inflammatory mediator. Recently, omaveloxolone (Omav), an activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, demonstrated clinically meaningful neurological benefits with a favorable safety profile.
Objectives
In this study, we report a 1-year follow-up of our real-life population treated with Omav, with a specific focus on clinical outcomes, safety, and inflammatory biomarkers.
Methods
Twenty patients with FRDA were evaluated for 48 weeks using clinical scales (mFARS, SARA, FSS, and FA-ADL) and laboratory testing. Inclusion criteria were genetically confirmed FRDA, age ≥ 16 years and mFARS <80. All patients received Omav 150 mg/day.
Results
Treatment showed a favorable safety profile, clinical stabilization and no serious adverse events with only one treatment discontinuation. IL-6 levels showed a progressive and significant reduction during follow-up. Transient hepatic enzyme elevations did not lead to treatment discontinuation.
Conclusions
Omav confirmed a favorable safety and tolerability profile in adult patients with FRDA in a real-world setting after 48 weeks of treatment. The sustained reduction in IL-6 levels further supports a potential direct immunomodulatory effect of the drug, consistent with its proposed disease-modifying activity. However, further long-term studies are warranted to better define the efficacy of Omav in FRDA.
Mutations in the tRNA Nucleotidyl Transferase 1 (TRNT1) gene have been associated with a systemic autoinflammatory disease (SAID) that presents with a wide clinical spectrum, ranging from severe and fatal forms to milder disorders. We conducted a literature review to provide a comprehensive analysis of the clinical cha...
Simona Di Gennaro, F. Della Casa, A. Petraroli et al.· Immuno· 0 citations
Importance
Leukoencephalopathies are clinically and etiologically heterogeneous disorders, and establishing a specific diagnosis remains challenging. Patients with unexplained spastic paraplegia and brain white matter hyperintensities (WMH) may be misdiagnosed as having multiple sclerosis, potentially exposing them to...
Yi-Heng Zeng, Bo-Li Chen, Yan Shi et al.· JAMA Neurology· 0 citations
Abstract INTRODUCTION Heterozygous progranulin gene mutations causing frontotemporal dementia (FTD‐GRN) are associated with deficiency in progranulin (PGRN). Latozinemab is a human monoclonal immunoglobulin G1 (IgG1) antibody designed to elevate PGRN levels in people with heterozygous loss‐of‐function (LOF) GRN mutatio...
Adam Simmons, B. Boeve, I. Le Ber et al.· Alzheimer's & Dementia· 0 citations
Introduction: Neuroinflammation is a known pathophysiologic mechanism in multiple sclerosis and a proposed mechanism in fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Positron Emission Tomography (PET) imaging of the translocator protein (TSPO) has been widely used to measure neuroinflamm...
Taxifolin (dihydroquercetin), a potent antioxidant flavonoid, shows promise for neurodegenerative conditions. Our pilot study aimed at evaluation the efficacy and safety of Taxifolin in patients with amnestic mild cognitive impairment (aMCI) and monitored a set of blood measures. Twenty-three patients (18 female; aged...
E. Ponomareva, N. Selezneva, I. Boksha et al.· Frontiers in Psychiatry· 0 citations
INTRODUCTION
Primary mitochondrial diseases (PMtD) are increasingly recognized to involve clinically meaningful immune dysregulation in addition to bioenergetic failure. Hyperinflammatory syndromes, including secondary hemophagocytic lymphohistiocytosis (HLH) and related cytokine-mediated inflammatory states, remain un...
Daniel Brooks, Eliza M. Gordon-Lipkin, I. Elsharkawi et al.· Molecular Genetics and Metab...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.